Research and resources
A library that puts peer-reviewed research and the essays of the people living this next to each other. Filter by phase, region or kind to find what's actually for you.
Talk to your doctor or specialist before changing treatment. Each article carries an Evidence A / B / C tag.
How to read this page →Evidence A / B / C
Strong: major guidelines, large randomized trials, or systematic reviews. Safe to act on.
Moderate: a solid trial or consistent observational studies. Worth considering, with nuance.
Early or limited: small studies, mixed results, or expert opinion. Useful context, not a basis for big calls.
Region tags
International bodies (WHO, IMS, Cochrane) or guidance that applies regardless of where you live.
Country-specific guidelines, regulators, or clinical bodies (e.g. SOGC, NAMS, NICE).
Lived experience and essays. Not pinned to a country, these stories travel.
Filtering by region keeps personal stories visible so you don't lose voices when you narrow the clinical view.
Have a study or essay you think belongs here? Send it our way and a moderator will review it for the library.
Reference shelf
The professional documents and journal pieces clinicians cite. Useful when you want to read the actual source behind the guidance.
by Ontario Health
Ontario's evidence-based quality standard for menopause care, covering assessment, treatment options, and follow-up. A useful reference for what guideline-concordant care looks like in Canada.
by Kearney (Paula Bellostas Muguerza, Anna Bode, Kate Maheu, Betty Pio)
While most employers have taken initial steps on women's health, true maturity requires integrated action connecting policy to lived experience through better communication, data use, and employee feedback.
by Menopause Mandate (with UCL support)
15,000+ women across the UK on what menopause support actually looks like: what's improved, what's still missing, and where urgent change is needed. Patient-led data at a scale most clinical cohorts don't reach.
by Jenny Castillo Cato, MD, FACEP (JMIR)
As FemTech matures into a $97B market, the priority must be deep, inclusive innovation that addresses chronic conditions and dismantles gender bias in research.
by Veradigm (Alina B., Isabelle Winer, Kate Cappell)
With data from 148M+ patients, this report surfaces sobering gaps: from the surging adolescent mental health crisis to the fact that fewer than 1 in 10 eligible women receive HRT. A powerful call to bridge the evidence-to-practice gap.
by Emmeline Ventures (La Keisha Landrum Pierre, Azin Radsan van Alebeek, Blessing Chukwuneke)
With 257 companies analyzed, this report highlights a stark funding gap: women founded nearly 60% of these firms, yet they receive only 32.5% of disclosed funding. Essential reading for understanding where venture capital is, and is not, placing its bets on reproductive health.
by The Persons Project (a My Normative initiative)
Synthesizes interviews with leaders across FemTech, academia, clinical research and life sciences to map the women's health knowledge gap, the vicious cycle of stagnation it creates, and a coordinated response: an open data ontology, shared research infrastructure, and an annual investment report.
by The Menopause Society (NAMS)
The current professional consensus document. Dense, but it's the thing your doctor's guidelines are based on.
by Crandall et al., Menopause (NAMS), 2017
The reference clinicians cite when discussing local vaginal estrogen for GSM after breast cancer. Cross-link from /treatments/cancer-risk.
by de Jong et al., 2023
One of the first peer-reviewed pieces naming the pattern clinicians are now seeing in clinic.
by Brinton et al., 2015
A foundational review that frames perimenopause as a brain event — estrogen withdrawal in regions dense with estrogen receptors drives sleep, mood and cognitive symptoms, not 'hormonal moodiness'.
by Barth et al., 2023
A wide-ranging review that ties the brain-estrogen story together from puberty through menopause, with direct relevance to depression and Alzheimer's disease risk.
by World Economic Forum, Kearney Health Institute, Gates Foundation, Wellcome Leap
Maps where women's health innovation is actually happening across funding, evidence and product pipelines. Names menopause as under-resourced relative to disease burden.
by The Menopause Society (NAMS)
The professional consensus document behind vaginal-estrogen, moisturizer and dyspareunia guidance. Explains why local estrogen is safe long-term for most women, including many after breast cancer.
by American Urological Association (AUA)
The current AUA guideline. Names pelvic floor physiotherapy as first-line (grade A), lays out the layered treatment stack, and is the reference to bring if your clinician is not familiar with IC.
by ISSVD, ISSWSH & IPPS
The consensus paper behind how vulvodynia and vestibulodynia are now diagnosed, subtyped and treated. Useful when you want to know why one specialist calls it vulvodynia and another calls it vestibulodynia.
by BMJ Editorial, 2025 (390: r1695)
Short, blunt BMJ editorial naming the current state of play: overclaims about HRT for prevention, underclaims about its use for symptoms, and the social-media amplification of both. A useful reference to hand a clinician or a family member who's confused by the noise.
No affiliate links. No paid placement. We update this shelf roughly every quarter.
Free for everyone, read smarter, not more
The internet has more menopause content than you can read in a lifetime. These three filters keep the noise out.
A randomized trial in The Lancet and a TikTok of someone's gut-feel are both 'studies' on Google. Knowing which is which is half the battle.
Try this week: Before you trust a claim, find the original. Look for: peer review, sample size, year, who funded it. If it's a single Instagram graphic with no link, close the tab.
